# UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

> **NCT02610543** · PHASE2 · TERMINATED · sponsor: **UCB Celltech** · enrollment: 27 (actual)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** UCB5857
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02610543
- **Lead sponsor:** UCB Celltech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2017-09-07
- **Final completion:** 2017-12-05
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Study stopped prematurely due to enrolment challenges.
- **Last updated:** 2020-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610543, "UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02610543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*